Shailly Gupta
@shaillygupta.bsky.social
Senior Communications Advisor, MSF Access Campaign. Avid follower of intellectual property and pro-access news. Believer of #ClaimingRightsNotCharity. Opinions are mine and doesn't represent my employer.
Denis from ITPC says that there are definitely access issues on the ground in Europe concerning bedaquiline by Johnson & Johnson
October 14, 2025 at 2:16 PM
Denis from ITPC says that there are definitely access issues on the ground in Europe concerning bedaquiline by Johnson & Johnson
Big Pharma never stops surprising us!
October 14, 2025 at 2:12 PM
Big Pharma never stops surprising us!
Price in Spain of 6 months BPaL regimen is as high as €58,000 per treatment course while the same drug regimen costs around €275 in low and middle income countries
October 14, 2025 at 1:44 PM
Price in Spain of 6 months BPaL regimen is as high as €58,000 per treatment course while the same drug regimen costs around €275 in low and middle income countries
Spain is far way from goals set for reducing TB in Europe as per Jaime
October 14, 2025 at 1:40 PM
Spain is far way from goals set for reducing TB in Europe as per Jaime
See our publication here where we share drug by drug access challenges in the EU and EEA. msfaccess.org/bridging-gap...
Bridging the gap: Securing access to essential TB medicines in the EU and EEA
MSF policy brief outlining barriers to accessing TB medicines in the EU/EEA region and recommendations to overcome them.
msfaccess.org
October 14, 2025 at 1:20 PM
See our publication here where we share drug by drug access challenges in the EU and EEA. msfaccess.org/bridging-gap...
A call by CSOs to make it available to all by overcoming patent and regulatory challenges #IDSky www.citizen.org/news/activis....
Activists Demand $40-a-year Generic Price for Breakthrough HIV Prevention Drug be Made Available to all Low- and Middle-Income Countries - Public Citizen
WASHINGTON, D.C. — A global coalition reacted to two deals announced today to make long acting lenacapavir (LEN-LA), a 6…
www.citizen.org
September 24, 2025 at 1:54 PM
A call by CSOs to make it available to all by overcoming patent and regulatory challenges #IDSky www.citizen.org/news/activis....
But not all countries benefit: some were excluded from Gilead’s license with generics—meaning they won’t get this ~$40 price msfaccess.org/gileads-volu...
Gilead’s Voluntary License on Lenacapavir: Key Limitations of the License and Recommendations to Improve Access
MSF briefing document outlines Gilead’s voluntary license for lenacapavir, highlights its limitations and challenges, and recommends actions to expand access.
msfaccess.org
September 24, 2025 at 1:54 PM
But not all countries benefit: some were excluded from Gilead’s license with generics—meaning they won’t get this ~$40 price msfaccess.org/gileads-volu...